WINSTON-SALEM, N.C., April 12, 2022 (GLOBE NEWSWIRE) -- ProKidney LP (“ProKidney”), a leading clinical-stage cellular therapeutics company focused on therapies for chronic kidney disease (“CKD”), ...
Clinical trials with REACT® have shown promising early efficacy and safety results. Individuals with Stage 3 and 4 type 2 diabetic CKD are target populations for restoration and stabilization of renal ...
WINSTON-SALEM, N.C., June 23, 2022 (GLOBE NEWSWIRE) -- ProKidney LP (ProKidney), a leading clinical-stage cellular therapeutics company focused on the treatment of chronic kidney disease (CKD) and the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results